HEALTHINVEST PARTNERS AB Holdings

HEALTHINVEST PARTNERS AB is an investment fund managing more than 47.34M US dollars. The largest holdings include Utah Medical Products, Bristol-Myers Squibb Company and Gilead Sciences. In Q3 2022 the fund bought assets of total value of 15.86M US dollars and sold assets of total value of 6.97M US dollars.

$47.34M

portfolio value

+1.09%

quarter

+4.97%

1 year

+42.75%

3 years

HEALTHINVEST PARTNERS AB portfolio changes

Portfolio changes (number of shares)
Period	Buy	Sel
Q1 2016	65203000	52130000
Q2 2016	35743000	30417000
Q3 2016	18119000	70888000
Q4 2016	27604000	47957000
Q1 2017	18738000	62530000
Q2 2017	41156000	20964000
Q3 2017	19566000	14216000
Q4 2017	10964000	49221000
Q4 2020	142769000	39155000
Q1 2021	33906000	59349000
Q2 2021	22882000	42910000
Q3 2021	35083000	73848000
Q4 2021	30344000	26141000
Q1 2022	20175000	25166000
Q2 2022	12766000	32192000
Q3 2022	15859000	6970000

HEALTHINVEST PARTNERS AB 13F holdings

Stock	Position type	Portfolio share	Portfolio value	Avg. open price	Current price	P/L	Last change
Medical Instruments & Supplies Utah Medical Products, Inc. Portfolio share: 15.50% Portfolio value: 7.33M Avg. open price: $93.53 Current price: $89.38 P/L: -4.43% Bought +53.57% shares Q2 2022	share	15.50%	7.33M	$93.53	$89.38	-4.43%	Bought +53.57% shares Q2 2022
Drug Manufacturers—General Bristol-Myers Squibb Company Portfolio share: 14.72% Portfolio value: 6.96M Avg. open price: $61.33 Current price: $81.33 P/L: +32.61% Bought +122.73% shares Q3 2022	share	14.72%	6.96M	$61.33	$81.33	+32.61%	Bought +122.73% shares Q3 2022
Drug Manufacturers—General Gilead Sciences, Inc. Portfolio share: 13.68% Portfolio value: 6.47M Avg. open price: $61.7 Current price: $88.98 P/L: +44.22% Bought +81.03% shares Q3 2022	share	13.68%	6.47M	$61.7	$88.98	+44.22%	Bought +81.03% shares Q3 2022
Healthcare Plans CIGNA CORP NEW Portfolio share: 9.96% Portfolio value: 4.71M Avg. open price: $243.64 Current price: $327 P/L: +34.22% Bought +21.43% shares Q3 2022	share	9.96%	4.71M	$243.64	$327	+34.22%	Bought +21.43% shares Q3 2022
Biotechnology KemPharm, Inc. Portfolio share: 9.89% Portfolio value: 4.68M Avg. open price: $4.94 Current price: $4.76 P/L: -3.70% Bought +11.94% shares Q3 2022	share	9.89%	4.68M	$4.94	$4.76	-3.70%	Bought +11.94% shares Q3 2022
Medical Distribution Cardinal Health, Inc. Portfolio share: 9.86% Portfolio value: 4.66M Avg. open price: $55.83 Current price: $79.93 P/L: +43.16% N/A Q3 2022	share	9.86%	4.66M	$55.83	$79.93	+43.16%	N/A Q3 2022
Medical Distribution McKesson Corporation Portfolio share: 9.33% Portfolio value: 4.41M Avg. open price: $175.25 Current price: $382.68 P/L: +118.36% Bought +30.00% shares Q3 2022	share	9.33%	4.41M	$175.25	$382.68	+118.36%	Bought +30.00% shares Q3 2022
Drug Manufacturers—Specialty & Generic Viatris Inc. Portfolio share: 8.64% Portfolio value: 4.09M Avg. open price: $10.47 Current price: $11.08 P/L: +5.83% Bought +54.84% shares Q3 2022	share	8.64%	4.09M	$10.47	$11.08	+5.83%	Bought +54.84% shares Q3 2022
Biotechnology Opiant Pharmaceuticals, Inc. Portfolio share: 4.77% Portfolio value: 2.25M Avg. open price: $21.42 Current price: $20.15 P/L: -5.93% Bought +1066.67% shares Q2 2022	share	4.77%	2.25M	$21.42	$20.15	-5.93%	Bought +1066.67% shares Q2 2022
Biotechnology Aurinia Pharmaceuticals Inc. Portfolio share: 3.65% Portfolio value: 1.73M Avg. open price: N/A Current price: $5.06 P/L: N/A N/A Q2 2022	share	3.65%	1.73M	N/A	$5.06	N/A	N/A Q2 2022
Biotechnology La Jolla Pharmaceutical Company Portfolio share: 0.00% Portfolio value: 0 Avg. open price: $4.13 Current price: $6.22 P/L: +50.61% Sold -100.00% shares Q3 2022	share	0.00%	0	$4.13	$6.22	+50.61%	Sold -100.00% shares Q3 2022
Biotechnology Harmony Biosciences Holdings, Inc. Portfolio share: 0.00% Portfolio value: 0 Avg. open price: $38.33 Current price: $61.41 P/L: +60.21% Sold -100.00% shares Q3 2022	share	0.00%	0	$38.33	$61.41	+60.21%	Sold -100.00% shares Q3 2022
Drug Manufacturers—General Biogen Inc. Portfolio share: 0.00% Portfolio value: 0 Avg. open price: N/A Current price: $293.47 P/L: N/A Sold -100.00% shares Q3 2022	share	0.00%	0	N/A	$293.47	N/A	Sold -100.00% shares Q3 2022

Showing TOP 13 HEALTHINVEST PARTNERS AB's 13F holdings.

Frequently Asked Questions (FAQ)

What is the biggest position of HEALTHINVEST PARTNERS AB?

The biggest position of the HEALTHINVEST PARTNERS AB is Utah Medical Products, Inc. (UTMD) with 15.5% portfolio share worth of 7.34M US dollars.

Top 5 HEALTHINVEST PARTNERS AB's holdings represent 63.74% of the portfolio:

Utah Medical Products, Inc. (UTMD) – 15.5%
Bristol-Myers Squibb Company (BMY) – 14.72%
Gilead Sciences, Inc. (GILD) – 13.68%
CIGNA CORP NEW (CI) – 9.96%
KemPharm, Inc. (KMPH) – 9.89%

Who is the portfolio manager of HEALTHINVEST PARTNERS AB?

The portfolio manager of the HEALTHINVEST PARTNERS AB is .

What is the total asset value of the HEALTHINVEST PARTNERS AB portfolio?

HEALTHINVEST PARTNERS AB total asset value (portfolio value) is 47.34M US dollars.

Who is ?

is the portfolio manager of the HEALTHINVEST PARTNERS AB.

What is (HEALTHINVEST PARTNERS AB) fund performance?

HEALTHINVEST PARTNERS AB's quarterly performance is +1.09%, annualy +4.97%. In the past 3 years, the value of 's portfolio has increased by +43%.

What is the HEALTHINVEST PARTNERS AB CIK?

HEALTHINVEST PARTNERS AB's Central Index Key is 0001381843 .